Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2022 | $20.00 → $11.00 | Overweight | Wells Fargo |
| 8/6/2021 | $17.00 → $15.00 | Buy | HC Wainwright & Co. |
Wells Fargo reiterated coverage of Celyad Oncology with a rating of Overweight and set a new price target of $11.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $15.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $17.00 from $18.00 previously
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) maximizing the value of its IP estate and (iii) driving innovation through strategic collaborations. MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 e
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd. Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2022 results and provide an update on the Company's recent changes and upcoming milestones. Participants may access the conference call by d
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibitory-molecule (TIM)-based allogeneic CAR T candidate CYAD-101 for metastatic colorectal cancer (mCRC)Company to increase strategic focus on collaborations related to broad intellectual property portfolioConference call and webcast scheduled for today, August 5th, at 2:00 p.m. CEST / 8:00 a.m. EDT MONT-SAINT-GUIBERT, Belgium, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Com
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a n
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration with the U.S. Securities and Exchange Commission (the "SEC") upon satisfaction of the requirements for deregistration. The Company will continue to be listed on Euronext Brussels. In connection w
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments. "Celyad Oncology is now fully committed to leveraging its expertise, know-how and intellectual p
15F-12B - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a notice from Nasdaq informing the Company that the minimum closi
Gainers Nanobiotix (NASDAQ:NBTX) stock increased by 125.6% to $4.58 during Friday's pre-market session. The company's market cap stands at $161.3 million. Star Equity Hldgs (NASDAQ:STRR) stock moved upwards by 24.63% to $0.86. The company's market cap stands at $13.0 million. Aditxt (NASDAQ:ADTX) stock rose 19.94% to $0.79. The market value of their outstanding shares is at $4.0 million. Telesis Bio (NASDAQ:TBIO) shares moved upwards by 17.81% to $3.24. The company's market cap stands at $96.0 million. Fulgent Genetics (NASDAQ:FLGT) stock increased by 15.7% to $33.0. The company's market cap stands at $979.8 million. The company's, Q1 earnings came out today. Owens & Minor (NYSE:OMI) s
SC 13D/A - Celyad Oncology SA (0001637890) (Subject)
SC 13D/A - Celyad Oncology SA (0001637890) (Subject)
SC 13D - Celyad Oncology SA (0001637890) (Subject)
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member. He spent four years at Celyad Oncology (2014-2018) as Vice-Presi
MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Ms. Windels has been a member of the Board of Directors since May 2018. Ms. Windels serves on multiple boards in the life sciences industry and has been an executive in the sector from 1999 through 2021, serving primarily as Chief Financial Officer and, over the last five years, as Chief Execu
Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC) ongoing; preliminary data expected in mid-2021.Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC expected to be initiated in first half of 2021. MONT-SAINT-GUIBERT, Belgiu